title: COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY.
abstract: OBJECTIVE
  To compare the efficacy of intravitreal injection of ranibizumab (IVR) monotherapy and laser therapy for treatment-requiring retinopathy of prematurity (ROP) in Zone II.
  
  
  METHODS
  A prospective, randomized, controlled single-center trial was applied from January 2014 to December 2014; infants who were diagnosed as Zone II treatment-requiring ROP (i.e., Zone II Stage 2 or 3 ROP with plus disease) were randomly assigned to receive IVR monotherapy or laser therapy, and the follow-up interval was at least 6 months. Any eyes that developed recurrence of ROP underwent crossover re-treatment.
  
  
  RESULTS
  A total of 100 eyes of 50 ethnic Han Chinese infants were enrolled. At the last follow-up, 26 eyes of 13 infants developed recurrence of ROP in the IVR group and 2 eyes of 1 infant developed recurrence of ROP in the laser therapy group. There was a significant statistical difference in the rate of ROP recurrence between IVR and laser therapy to treat Zone II treatment-requiring ROP (P = 0.001).
  
  
  CONCLUSIONS
  Although IVR appears to regress ROP to certain levels and continue to promote the vascularization of peripheral retinal vessels, a substantial proportion of infants developed recurrence of ROP after a single-dose IVR. Therefore, IVR is not recommended as a single-dose monotherapy for Zone II treatment-requiring ROP.
authors.affiliation: *Pediatric Retinal Surgery Department, Shenzhen Eye Hospital, Shenzhen Key Ophthalmic Laboratory, The Second Affiliated Hospital of Jinan University, Shenzhen, China; †Department of Ophthalmology, Royal Free Hospital, London, United Kingdom; ‡Department of Ophthalmology, Kunming City Women and Children Health Hospital, Kunming, China; and §Department of Monitor and Assess, Shenzhen Health Education and Promotion Center, Shenzhen, China.
authors.forename: Guoming
authors.initials: G
authors.lastname: Zhang
authors.forename: Mingmin
authors.initials: M
authors.lastname: Yang
authors.forename: Jian
authors.initials: J
authors.lastname: Zeng
authors.forename: Georgios
authors.initials: G
authors.lastname: Vakros
authors.forename: Kangjin
authors.initials: K
authors.lastname: Su
authors.forename: Miaohong
authors.initials: M
authors.lastname: Chen
authors.forename: Huilin
authors.initials: H
authors.lastname: Li
authors.forename: Ruyin
authors.initials: R
authors.lastname: Tian
authors.forename: Na
authors.initials: N
authors.lastname: Li
authors.forename: Song
authors.initials: S
authors.lastname: Tang
authors.forename: Honghui
authors.initials: H
authors.lastname: He
authors.forename: Wenjing
authors.initials: W
authors.lastname: Tan
authors.forename: Xiangmei
authors.initials: X
authors.lastname: Song
authors.forename: Runsen
authors.initials: R
authors.lastname: Zhuang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D053685:Laser Therapy / Q000379:methods*; D011446:Prospective Studies; D000069579:Ranibizumab / Q000008:administration & dosage*; D012008:Recurrence; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000601:surgery*
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab